UCB.BR - UCB SA

Brussels - Brussels Delayed price. Currency in EUR
66.24
+0.60 (+0.91%)
At close: 5:35PM CEST
Stock chart is not supported by your current browser
Previous close65.64
Open65.90
Bid64.00 x 203800
Ask66.00 x 10000
Day's range65.62 - 66.24
52-week range56.55 - 71.28
Volume320,910
Avg. volume311,926
Market cap12.467B
Beta0.81
PE ratio (TTM)16.58
EPS (TTM)3.99
Earnings date26 Jul 2018
Forward dividend & yield1.18 (1.80%)
Ex-dividend date2018-04-27
1y target est69.16
  • PR Newswire4 days ago

    UCB Joins with ILAE and IBE to Encourage World Health Assembly Members to Continue Recognition of Epilepsy as Global Health Priority

    Representatives from the International League against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE), alongside prominent members of the Global epilepsy community, are meeting this week to encourage World Health Assembly (WHA) members and the World Health Organization (WHO) to continue to recognize epilepsy as a global health priority in countries around the world. Coinciding with the 71st World Health Assembly, advocates will focus on progressing the milestone 2015 WHO Resolution on epilepsy to encourage countries to prioritise epilepsy at national levels, including promoting awareness, eliminating stigma of the disease, expanding research capacity, improving monitoring and surveillance, and expanding access to care.

  • PR Newswire12 days ago

    UCB Announces BRIVIACT® (Brivaracetam) now Approved by FDA to Treat Partial-onset (Focal) Seizures in Pediatric Epilepsy Patients

    UCB announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for the company's newest anti-epileptic drug (AED) BRIVIACT® (brivaracetam) CV oral formulations indicated as monotherapy and adjunctive therapy in the treatment of partial onset (focal) seizures in patients age four years and older. This approval provides clinicians with the convenient option to prescribe BRIVIACT to their pediatric patients as a tablet or oral solution, providing flexible administration options which are important considerations when treating children.

  • PR Newswirelast month

    UCB to Expand Epilepsy Portfolio With Strategic Acquisition of Midazolam Nasal Spray From Proximagen

    Midazolam Nasal Spray (USL261), is a nasally administered investigational midazolam formulation intended as a rescue treatment of acute repetitive seizures (ARS) in patients with epilepsy, which has completed Phase 3 clinical development and is ready to be filed as a New Drug Application (NDA) in the course of 2018. Nasal administration could provide significant value to patients who currently have limited treatment options.

  • PR Newswire2 months ago

    UCB Strengthens Research Capabilities With Acquisition of Element Genomics, a Duke University Biotech Spin-off

    UCB announces the acquisition of Element Genomics, a small-size biotech spin-off from Duke University, based in Durham, North Carolina (USA). At the core of the Element Genomics platform is a suite of technologies to improve understanding of genome structure and function such as CRISPR editing technologies used for genomic and epigenomic regulatory region analysis and modulation, underpinned and enabled with advanced informatics capabilities, and driven by a strong scientific team. Element Genomics' proven technologies and expertise will enhance UCB's scientific research platform enabling the company to continue to enrich its pipeline, in particular strengthening target discovery and characterization in disease relevant systems.

  • GlobeNewswire2 months ago

    UCB: CONVENING NOTICE TO ATTEND THE GENERAL MEETING OF SHAREHOLDERS TO BE HELD AT BLUEPOINT BRUSSELS

    *** Unofficial English translation - For convenience purposes only ***     UCB SA/NV - Public Limited Liability Company Allée de la Recherche 60, 1070 Brussels Enterprise nr. 0403.053.608 (RLE Brussels) ...

  • Regulus Therapeutics (RGLS) Looks Good: Stock Adds 5.6% in Session
    Zacks8 months ago

    Regulus Therapeutics (RGLS) Looks Good: Stock Adds 5.6% in Session

    Regulus Therapeutics Inc. (RGLS) was a big mover last session, as the company saw its shares rise nearly 6% on the day amid huge volumes

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes